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Abstract
Background: Platelet-rich plasma (PRP) is a human plasma product enriched by platelets, growth factors, and fibrinogen with high
hemostatic and healing properties.
Objectives: The aim of this study was to evaluate the effect of autologous PRP on wound healing in high-risk women undergoing
cesarean sections.
Patients and Methods: In this balanced, randomized, and controlled trial, 140 patients were admitted to Arash women’s hospital,
Tehran, Iran from May of 2013 to November of 2014 for elective cesarean surgery. The patients were randomly assigned into two
groups. The intervention group received PRP after surgery, whereas the control group received the usual care. All patients were
evaluated at baseline, five days, and eight weeks after the cesarean section. The primary endpoint used the REEDA scale for assessing
the changes in wound healing. The secondary outcome measures used were the Vancouver scar scale (VSS) and the visual analog
scale (VAS). All scale scores were analyzed using a repeated measures test for variance.
Results: At the end of study, the PRP group showed a greater reduction in the edema ecchymosed discharge approximation (REEDA)
score compared to the control group (85.5% reduction in the PRP group; 72% in the control group) (P < 0.001). Compared with the
control group, the PRP group had a significantly greater reduction in the VAN score, beginning on the fifth day after the cesarean sec-
tion (-0.7, 38% reduction in PRP group; -0.8, 33% in control group) (P < 0.001), and this trend was stable at the end of the eighth week
(-0.6, 54% reduction in PRP group; -0.3, 18% in control group). Furthermore, patients treated with PRP experienced a 93% reduction
in the VAS score at the end of follow-up, but the control group only observed a 79% reduction (P < 0.001).
Conclusions: It seems that applying PRP is an effective therapeutic approach for wound healing, and faster wound healing is ex-
pected due to the presence of more platelets and growth factors.
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1. Background
Caesarean deliveries are used for 15% of births around
the world, and this rate has continued to increase (1).
These deliveries have become a major concern in develop-
ing countries such as Iran, with a high rate of 47.9% for
caesarean sections (2). The postpartum period is a diffi-
cult and challenging time for mothers, especially due to
the requirements of caring for a newborn baby. Surgical
site complications such as infection, hematoma, seroma,
dehiscence, and pain may occur in the puerperal pe-
riod. These complications are associated with substan-
tial morbidity and mortality, prolonged hospital stay, and
increased cost. Therefore, reduction in the incidence of
these morbidities would cut down on medical expenses
and improve maternal and neonatal care (3). Several risk
factors affect the wound healing process in caesarean sec-
tions, including: (1) twin birth, (2) chronic systemic dis-
ease (diabetes, hypertension, and immune deficiencies),
(3) surgery duration > 90 minutes, obesity, (4) previous in-
cision, (5) corticosteroid therapy, (6) immunosuppression
treatment, and (7) anemia (4, 5).
Surgical wounds heal through an orderly sequence of
several distinct physiological and biological events that in-
clude hemostasis, inflammation, proliferation, epithelial-
ization, fibroplasia, and maturation (6, 7). This process is
initiated immediately upon injury. A platelet plaque de-
velops which is composed of platelets and fibrin, and the
platelets release granules containing multiple growth fac-
tors and thromboxane A2, the latter of which acts as a
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potent vasoconstrictor. Transforming growth factor beta
(TGF-β) is the key growth factor that plays a central role in
wound healing. In a wound site, following the clot forma-
tion, platelets and mesenchymal stem cells release their
complex contents in the wound healing process. The max-
imum tensile strength of the tissue is reached approxi-
mately eight weeks after injury (6). In vitro studies on
the proliferation of mesenchymal stem cells (MSC) con-
firmed that PRP improves MSC proliferation and differenti-
ation, suggesting a high regenerative potential of PRP (8).
Platelet-rich plasma (PRP) has been used for more than a
decade in injectable or gel form (9), and many studies have
demonstrated that PRP stimulates regeneration of the soft
tissues (fat, skin, and mucosa) (10, 11) as well as the hard tis-
sues (tendons and bones) (12, 13). However, there are many
clinical studies that have been published with a wide range
of results, and the evaluation of the influence of PRP on
wound healing and pain remains variable. Although most
studies have concluded that PRP is safe with positive ef-
fects, others have indicated conflicting results (10-14).
2. Objectives
In this study we attempted to evaluate the efficacy of
topical application of autologous PRP in treatment for the
wound healing process and the perception of pain in high
risk patients who underwent cesarean sections.
3. Patients and Methods
3.1. Trial Design
This was a balanced, randomized, and controlled trial
that was performed on 140 candidates for cesarean de-
livery who were admitted to Arash women’s hospital in
Tehran, Iran between May of 2013 and November of 2014.
Arash women’s hospital is a general women’s hospital lo-
cated in Tehranpars, an eastern suburb of Tehran. It is an
educational, research, and treatment center for gynecol-
ogy and obstetrics.
A research protocol including methods, considered
outcomes, sample size calculation, and ethical consider-
ations was produced prior to the initiation of the trial.
The study protocol was approved by the institutional re-
view board of Tehran University of Medical Sciences. In-
formed consent was obtained from all participants and the
study was registered in Iranian registry of clinical trials
(www.IRCT.ir) under the number IRCT2014111618866N3.
3.2. Participants
All cesarean sections were carried out in a training
hospital and under the supervision of senior residents,
and all of the patients received preoperative intravenous
cephalothin (2 gr). The inclusion criteria were body mass
index (BMI) > 25, prior cesarean section, diabetes or gesta-
tional diabetes, twin pregnancy, use of corticosteroid med-
ication, and anemia. The exclusion criteria were chronic
pain disorders, hepatitis, hemoglobin (Hb) < 9 mmol/L, co-
agulation disorders, and platelet levels < 150× 106/L.
3.3. Interventions
In the operating room before the start of each proce-
dure, approximately 55 cc of whole blood was drawn from
the uninvolved arm of each patient in the intervention
group (group A) into a 60 ml sterile syringe containing cit-
rate for anticoagulation. The blood was immediately cen-
trifuged at 3200 PRM. Following 15 minutes of centrifu-
gation, 4 - 5 mL of PRP was obtained. Then, the PRP was
buffered by using sodium bicarbonate. All of the proce-
dures were conducted in an operation room with the pur-
pose of safe guarding sterilization. After closure of the fas-
cia and prior to skin closure, PRP was directly applied to
the subcutaneous tissue of the wound site by using a ster-
ile syringe. In the control group (group B), the patients re-
ceived no topical treatment and the subcutaneous tissue
was cleaned with normal saline before skin closure. For all
participants, no drains were used and the skin was closed
with intracutaneous Monocryl 2-0 according to the proce-
dures of routine care. After skin closure, a wound dressing
with a compressed bandage was applied. The patients were
examined by the physicians who were blind to group allo-
cation of the patients on day 1, and then five days and eight
weeks after the procedure. Pain was evaluated by the visual
analog scoring system (VAS). The wound healing was evalu-
ated by using the Vancouver scar scale (VSS) and the edema
ecchymosed discharge approximation (REEDA) scale.
3.4. Outcomes
The primary endpoint used the REEDA scale for assess-
ing the changes in wound healing. REEDA as a descrip-
tive scale has 4 points in a categorical score that measures
5 items of healing: redness (hyperaemia), edema, ecchy-
mosis, discharge, and approximation of the wound edges
(coaptation). Each item is rated on a scale of 0 to 3, and to-
tal scores may range from 0 to 15. A lower score indicates
better healing (15).
The secondary outcomes were measured by VSS and
VAS. VSS was used to detect formation of keloids or hyper-
trophic scars. It assesses 4 subjective variables: vascular-
ity, height/thickness, pliability, and pigmentation within
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a possible range of 0 - 14 for the total score (16). The VAS
assesses pain via a continuous measurement instrument
that is operationally comprised of a horizontal line, an-
chored at each end by verbal descriptors such as no pain
and the worst pain imaginable. The subject is asked to in-
dicate a spot on the scale that best represents her degree of
pain. The score is determined by measuring the distance
(mm) between the no pain anchor to the point that the pa-
tient marks, providing a range of scores from 0 - 100. A
higher score indicates greater pain intensity (17).
3.5. Sample Size
Based on an expected mean of 7.3 and standard devia-
tions of 1.5 and 6.5, and 1.4 of the primary endpoint (REEDA)
in the control and intervention groups, respectively, we
determined that we would need a sample size of 70 pa-
tients in each group for 80% reliability in detecting a signif-
icant difference between the treatment and control groups
(with two-sided type 1 error of 5%).
3.6. Randomizations
Patients were randomly assigned into two groups us-
ing a random number sequence generated by statistical
software and stratified with a 1: 1 allocation using random
block sizes of 6. A randomization list prepared by an epi-
demiologist was inserted into a set of numbered sealed
envelopes. Whenever a patient was found to have quali-
fied and had consented to participate in the trial, the num-
bered envelope was opened to determine the intervention
technique. Participants and outcome assessors did not
know which group they had been assigned to for the du-
ration of the study.
3.7. Statistical Methods
Statistical analysis was performed by using computer
software SPSS 18 for windows. We compared the difference
between the baseline characteristics of patients after ran-
domization into the two groups with a chi-square test for
the different categories and with a student’s t-test for con-
tinuous variables. Values of P = 0.05 were considered sta-
tistically significant. The endpoint mean of the REEDA,
VSS, and VAS scores were analyzed using repeated mea-
sures analysis of variance. The model included treatment
as a fixed factor along with age, platelet count, hemoglobin
count, body mass index (BMI), REEDA score, VSS score, and
VAS score at baseline as covariates.
4. Results
Between May of 2013 and November of 2014, 194 pa-
tients were enrolled in the study. Of the 138 eligible pa-
tients, 67 patients were assigned to the treatment group
and 71 to the control group. The analysis was determined
by intention-to-treat and included all patients who were
randomly assigned. Figure 1 shows the trial profile. In both
groups, almost half of the patients were primigravida, and
there was no difference between the two groups in terms
of the gravidity. Also there was no significant difference
between the two groups regarding their hemodynamic in-
dices or blood groups. The groups were well matched at
the baseline and the characteristics of the patients did not
differ dramatically. The baseline demographic and clinical
characteristics are summarized in Table 1.
Mauchly’s sphericity test indicated that the assump-
tion of sphericity had been established as χ2 (2) = 0.223,
P = 0.89. The means of the primary and secondary out-
comes for three measured times for both groups are shown
in Table 2. In the analysis of the overtime scores, the PRP
group had lower scores compared to control group for all
measures. After five days, the reduction in the REEDA score
for the PRP group was -1.03, a 43% reduction. This trend
was constant overtime and the results after eight weeks
showed a decrease of -0.57, a 42.5% reduction. A similar
trend was observed in the control group: after five days,
the reduction in the REEDA score was -0.64, a 25% reduc-
tion, and after eight weeks, there was a -0.87 decrease, or a
47% reduction (Figure 2).
The general analysis with repeated measures showed
that treatment with PRP had a significant effect on reduc-
ing the REEDA score compared with the treatment of the
control group (F (1, 132) = 7.28, P = 0.008). For the secondary
end point (VAN score), the results showed that treatment
with PRP had a significant effect on reducing the score
compared with the treatment of the control group (F (1,
132) = 50.55, P < 0.001). Compared with the control group,
the PRP group had a significantly greater reduction in the
VAN score beginning on the fifth day (-0.7, 38% reduction
in the PRP group; -0.8, 33% in the control group) and this
trend was stable at the end of the eighth week (-0.6, 54% re-
duction in the PRP group; -0.3, 18% in the control group)
(Figure 3)
The changes in the mean of the VAS score over time are
illustrated in Figure 4. Patients treated with PRP experi-
enced a -1.7 decrease, or a 42% reduction, in the VAS score at
5 days, and after 8 weeks of the study, the observed decline
was -1.17, a 51% reduction. A similar trend was observed in
the control group: after 5 days, there was a decrease of -1.53,
a 31% reduction, and after eight weeks, there was a -1.6 de-
crease, or a 48% reduction (Figure 4). Repeated measures
analysis showed a significant effect on the VAS score in fa-
vor of PRP (F (1, 132) = 80.15, P < 0.001).
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Figure 1. Flowchart Showing Participants and Group Disposition
Table 1. Clinical Characteristics of the Patients by Either Platelet-Rich Plasma (PRP) Treatment or the Control Groupa
Characteristics PRP (n = 67) Control (n = 71) P Value
Maternal age in years, mean± SD 29.55± 5.45 28.05± 5.25 0.057
Gravidity, mean± SD 1.57± 0.64 1.69± 0.89 0.383
Previous cesarean scar 17 (25.37) 16 (22.53) 0.843
History of immunodeficiency 1 (1.49) 0 (0) 0.49
History of diabetes 5 (7.46) 10 (14.08) 0.2
History of anemia 9 (13.43) 13 (18.3) 0.3
Corticosteroid usage 8 (11.94) 11 (15.49) 0.4
aValues re expressed as No. (%) unless otherwise indicated.
5. Discussion
Complications of the wounds in cesarean sections is
an unresolved problem and remains one of the common
causes of puerperal morbidity. Topical application of PRP
as a novel method with the potential to prevent post-
operative wound infection, enhance the wound healing
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Table 2. Means of REEDA, VAS, and VAS Scores for the Two Groups During the Studya
Groups Time P Value
Day 1 Day 5 Week 8
REEDA score P < 0.001
PRP 2.37± (0.71) 1.34± (0.59) 0.77± (0.51)
Control 2.49± (0.58) 1.85± (0.61) 0.98± (0.52)
VAN score P < 0.001
PRP 1.8± (0.6) 1.1± (0.65) 0.5± (0.56)
Control 2.39± (0.9) 1.59± (0.64) 1.29± (0.7)
VAS score P < 0.001
PRP 3.98± 0.63) 2.28± (0.79) 1.11± (0.84)
Control 4.83± (0.95) 3.3± (1.26) 1.7± (0.74)
aValues are expressed as mean± SD.
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Figure 2. Improvement From the Baseline in the Means of the VSS Scores Over Time
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Figure 3. Improvement From the Baseline in the Means of the REEDA Scores Over
Time
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Figure 4. Improvement From the Baseline in the Means of the VAS Scores Over Time
process, and reduce pain and other adverse events has
been acknowledged by the surgical community. PRP is
a volume fraction of blood having a high concentration
of platelets above the baseline that markedly improves
the adhesive properties and the process of wound healing
(18, 19). After application of PRP, the tissue-healing sub-
stances are released. The supra-physiological concentra-
tion of platelets at the wound site accelerate the healing
process and protect the wound against the infection (18-21).
Because of its physiological role in wound healing, PRP
is being used more often for a variety of clinical applica-
tions, and it is now popular to apply it as a part of routine
treatment. However, it still remains uncertain whether the
impact of topical application of PRP is a fact or a fiction
(22). We found that patients who were treated with topi-
cal autologous PRP (group A) had a significant reduction in
pain, keloids, and hypertrophic scar formation, and they
experienced better wound healing after surgery in com-
parison with the control group (group B) (P < 0.0001).
None of 67 patients in group A developed adverse events.
Similar results were found by Fanning and colleagues (3).
This study was performed on 55 patients undergoing gy-
necologic surgeries such as hysterectomies and advanced
urogynecological and laparoscopic procedures. A non-
randomized clinical outpatient trial with a follow-up was
conducted for 28 days, and the authors showed that there
was a significant reduction in pain (P < 001). Also, narcotic
use was reduced for nearly 50% in the treated patients com-
pared with the control subjects.
Other studies similar to the one presented here have
concluded that PRP improves the wound healing process
(10, 22, 23). However, in contrast to the results of this study,
some authors have shown the failure of PRP in promoting
wound healing (13, 14, 24). One such study was a double-
blind randomized and controlled trial which used auto-
logues platelet gel after total knee arthroplasty on 102 pa-
tients with a 3-month follow up. The authors have con-
cluded that there was no positive effect of the autologues
platelet gel on wound healing. They have also indicated
that it had no effect on pain or hemoglobin values (24).
Everts et al. (25) applied platelet-leukocyte gel on 40
patients who underwent open subacromial surgery and
showed that the VAS for pain had been decreased. They
also demonstrated a significant reduction in recovery time
and analgesic usage during the 6-week follow-up. The VAS
score was 2.0 ± 2.0 and 1.1 ± 0.3 in the control and treat-
ment groups, respectively, which were the same as the
present study, whereas the mean VAS in the PRP and the
control group at the first day, fifth day, and eighth week
after surgery were 0.6 ± 0.07, 0.96 ± 0.11, and 2.2 ± 0.79
vs. 3.3± 1.2, and 1.11± 0.84 vs. 1.7± 0.75, respectively. This
study did not evaluate analgesic usage and dose. Further-
more, it is assumed that the serotonin released from the
activated platelets may be responsible for pain reduction
(16). This phenomenon was explained by Sprott et al. in a
study claiming that serotonin is released from platelets af-
ter acupuncture therapy and causes pain reduction (26).
The present study had the following limitations: First,
it was not double-blind, and this could have generated bi-
ases. Second, the pain was not measured by the use of anal-
gesics. Third, it had a short-term follow-up period. Fourth,
we did not investigate the effects of varying platelet con-
centrations. Currently, there are numerous studies with
variable evidence. Variants can be related to many factors
including health status, donor variability, centrifuge dura-
tion and speed, platelet concentration, or different types
of wounds and tissues, among other factors. Clearly it is
necessary to perform further multicentric, controlled, and
double-blind clinical trials with similar and standard pro-
tocols to assess the potential influences of PRP until more
conclusive evidence becomes available.
5.1. Conclusion
The present study is the first prospective, randomized,
and controlled trial evaluating the efficacy of autologous
PRP in cesarean section surgery, and it has demonstrated
that PRP has positive effects on wound healing and pain re-
duction in high-risk patients undergoing cesarean section.
There are plans to design and conduct a similar but more
comprehensive study on women who will undergo gyne-
cologic cancer surgery.
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